Mineralys Therapeutics, Inc. (MLYS) Financial Statements
Free cash flow over the same period: -$138.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLYSMineralys Therapeutics, Inc.Follow MLYS — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Research & development | 70.4 | 168.6 | 132.0 | 301.6 | |
| Operating income | -84.7 | -192.4 | -170.6 | -370.8 | |
| Pre-tax income | -71.9 | -177.8 | -154.7 | -349.6 | |
| Income tax | — | — | 0.0 | — | |
| Net income | -71.9 | -177.8 | -154.7 | -349.6 | |
| Diluted EPS ($) | -1.99 | -3.66 | -2.29 | -4.13 | |
| Diluted shares (mn) | 36.2 | 48.5 | 67.7 | — |
USD millions · SEC XBRL
Mineralys Therapeutics, Inc. — questions
- What is Mineralys Therapeutics, Inc.'s net income?
- -$349.6M over the twelve months to 2026-06-30.
- What is Mineralys Therapeutics, Inc.'s free cash flow?
- -$138.8M over the twelve months to 2026-06-30.
- What are Mineralys Therapeutics, Inc.'s diluted earnings per share?
- $-4.13 over the twelve months to 2026-06-30.
Every figure on this page comes from Mineralys Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.